A Look At Humana (HUM) Valuation After Earnings Miss And Lower Full Year Guidance

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.

Humana stock in focus after earnings and guidance shift

Humana (HUM) is back on investors’ radar after first quarter results, a lower full year earnings outlook, and confirmation that the company has completed a previously announced share repurchase program.

See our latest analysis for Humana.

The latest earnings release and lower full year guidance have coincided with a sharp 33.81% 1 month share price return. However, Humana’s 1 year total shareholder return of 5.83% and 3 year total shareholder return of 53.98% remain weak, suggesting recent momentum follows a tougher multi year stretch for holders.

If Humana’s move has you thinking about where else capital might work hard in healthcare, this is a good moment to scan 33 healthcare AI stocks

With Humana trading close to analyst targets but carrying an intrinsic value estimate that implies a large discount, the key question for you is whether recent weakness represents a real opportunity or whether the market already reflects future growth.

Most Popular Narrative: 11.8% Overvalued

Humana’s last close at $237.96 sits above the narrative fair value of $212.87, putting investor attention on what is driving that gap.

Humana’s current pressures underscore that reality. As Medicare Advantage continues to expand, the companies that thrive will likely be those that treat compliance not as a checkbox, but as an operational framework embedded into every layer of their billing and clinical review systems.

Read the complete narrative.

Regulation sits at the center of this valuation story. The narrative, according to yiannisz, leans heavily on how compliance, documentation quality, and Medicare Advantage scale interact with margins and long term cash generation. Want to see which assumptions about future profitability and growth keep the fair value below today’s price.

Result: Fair Value of $212.87 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this narrative could be knocked off course if regulatory intensity eases, or if Humana’s compliance investments materially reduce audit and documentation risks.

Find out about the key risks to this Humana narrative.

Another View: Earnings Multiple Sends a Different Signal

While the narrative fair value of $212.87 points to Humana as 11.8% overvalued, the current P/E of 25.3x tells a different story. It sits below the estimated fair ratio of 39.4x and under the 32.4x peer average, even though it is slightly above the 24.9x US Healthcare industry level.

In practical terms, that mix of discounts and premiums suggests investors are pricing in some business specific risk, yet still leaving room for the P/E to move closer to the fair ratio if sentiment or earnings expectations change. The real question for you is whether that gap feels like a margin of safety or a valuation trap.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

If this all feels like a mixed message, that is exactly why it pays to look under the hood yourself and move quickly to form an opinion using the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If Humana has your attention, do not stop here. Broadening your watchlist with different types of opportunities can help you stress test your thinking and avoid tunnel vision.

Put the Simply Wall Street Screener to work and quickly surface stocks that match the kind of risk, quality, and income profile you want.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include HUM.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com